Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

DIAS-2 stroke study of desmoteplase completes enrollment

Dec. 13, 2006

ReGen explores effects of zolpidem in people with brain damage

Dec. 13, 2006

Recent patents report novel analgesic agents

Dec. 13, 2006

Allon cleared to begin phase II study of AL-108 in mild cognitive impairment

Dec. 13, 2006

Calpain inhibitor delays disease severity and progression in a mouse model of multiple sclerosis

Dec. 13, 2006

Human opiorphin potentiates analgesic effects of enkephalins by inhibiting their degradation

Dec. 13, 2006

Novel agents for treating neurological disorders disclosed in recent Neuren and Santhera patents

Dec. 12, 2006

Iloperidone demonstrates statistical significance in schizophrenia

Dec. 12, 2006

Lexapro provides greater reduction in MADRS scores than Cymbalta in MDD

Dec. 12, 2006

AC Immune and Genentech enter agreement for anti-beta-amyloid antibodies

Dec. 12, 2006

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...